Shots: The P-III ARAMIS trial involves assessing of Darolutamide (600 mg, bid) + androgen deprivation therapy (ADT) vs PBO + ADT in 1509 patients in the ratio (2:1) with nmCRPC […]readmore
Tags : Bayer
Shots: Moberg to receive $1.69M upfront, $56.39M milestone, royalties & supply fees based on sales of MOB-015. Bayer to get exclusive commercialization rights for MOB-015 in EU post completion of […]readmore
Shots: Bayer and Kyoto University collaborate to jointly conduct clinical trials for identifying targets in lung diseases. Bayer will have an exclusive option to license the developed product in the […]readmore
Shots: The CHMP of EMA approval is based on P-II/III PROTECT VIII trial assessing BAY94-9027 in patients ≥12 years treated previously with severe haemophilia A, (74% receiving BAY94-9027 qw) and […]readmore
Shots: The agreement includes drug for treatment of acne, fungal skin infections and rosacea, and a range of topical steroids summing up an annual turnover of ≥280 Mn Euros in […]readmore